• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Movano Inc.

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MOVE alert in real time by email
    SC 13G 1 ea0203615-13gappel_movano.htm SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Movano, Inc.

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    62459M107

    (CUSIP Number)

     

    April 4, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

    (Continued on following pages)

     

     

     

     

     

     

    CUSIP No. 62459M107

     

    1

    NAME OF REPORTING PERSONS

     

    Peter A. Appel

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐
    (b) ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

      9,722,104
    6

    SHARED VOTING POWER

     

      0
    7

    SOLE DISPOSITIVE POWER

     

      9,722,104
    8 SHARED DISPOSITIVE POWER

    0
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,722,104

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%(1)

    12 TYPE OF REPORTING PERSON

    IN

     

    (1)Based on the 98,203,068 shares of Common Stock outstanding as of April 9, 2024.

     

    2

     

     

    Item 1(a). Name of Issuer:

     

    Movano, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    6800 Koll Center Parkway

    Pleasanton, CA 94566

     

    Item 2(a). Name of Person Filing:

     

    Peter A. Appel

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    3505 Main Lodge Drive

    Coconut Grove, FL 33133

     

    Item 2(c). Citizenship:

     

    United States

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock

     

    Item 2(e). CUSIP Number:

     

    62459M107

     

    Item 3. Not applicable.

     

    Item 4. Ownership.

     

      (a)

    Amount beneficially owned:

     

    As of the close of business on April 9, 2024, Peter Appel (the “Reporting Person”) held (i) 9,722,104 shares of Movano Inc.’s (the “Issuer”) Common Stock, (ii) 2,420,844 pre-funded warrants to purchase one share of the Issuer’s Common Stock (the “Pre-Funded Warrants”), and (iii) 9,568,000 Warrants to purchase one share of the Issuer’s Common Stock (the “Warrants”); provided the holder of Pre-Funded Warrants and/or Warrants does not have the right to exercise any portion of its Pre-Funded Warrants and/or Warrants to the extent that the holder (together with its affiliates) would beneficially own more than 9.99% of the shares of Issuer Common Stock outstanding immediately after such exercise.

     

      (b) Percent of class: See responses to Item 11 on the attached cover page.

     

      (c) Number of shares as to which the person has:

     

      (i)

    Sole power to direct the vote:

     

    See responses to Item 5 on the attached cover page.

     

      (ii)

    Shared power to direct the vote:

     

    See responses to Item 6 on the attached cover page.

     

    3

     

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

    See responses to Item 7 on the attached cover page.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

     

    See responses to Item 8 on the attached cover page.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 10, 2024

     

    /s/ Peter A. Appel  
    Name: Peter A. Appel  

     

     

    [Signature page to Schedule 13G]

     

    5

     

    Get the next $MOVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MOVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:31:04 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)

    4 - Corvex, Inc. (0001734750) (Issuer)

    7/8/26 6:30:26 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Caballero Ruben bought 22,000 shares, increasing direct ownership by 38% to 80,200 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/12/24 4:30:19 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Fairbairn Emily bought 4,690,000 shares (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:08 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cogan Jeremy bought 45,000 shares, increasing direct ownership by 6% to 780,649 units (SEC Form 4)

    4 - Movano Inc. (0001734750) (Issuer)

    4/4/24 5:30:14 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    SEC Filings

    View All

    SEC Form S-1 filed by Corvex Inc.

    S-1 - Corvex, Inc. (0001734750) (Filer)

    7/10/26 5:10:53 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Corvex, Inc. (0001734750) (Filer)

    7/7/26 5:10:57 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by Corvex Inc.

    S-8 - Corvex, Inc. (0001734750) (Filer)

    7/1/26 4:58:37 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Leadership Updates

    Live Leadership Updates

    View All

    Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations

    Former Crusoe leader brings 25 years of experience across HPC architecture, GPU infrastructure, and site operationsARLINGTON, Va., July 15, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Michael Craig as Vice President of Architecture and Site Operations. Craig will lead cluster architecture and site operations for Corvex's AI Factory business, helping coordinate the technical, physical and supply-chain requirements necessary to convert high-density GPU infrastructure into reliable, prod

    7/15/26 9:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex Stockholders Approve Key Governance and Capital Structure Proposals at 2026 Annual Meeting

    Company Disposes of Legacy Movano Assets; Shareholders Elect Three New Directors; Approve Conversion of Series C and Series D Preferred Stock; Chance Moreland Joins as CFOARLINGTON, Va., July 1, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the results of its 2026 Annual Meeting of Stockholders, held virtually. Shareholders voted to approve all proposals before them, including the election of three new directors to the Company's Board, authorization of the

    7/1/26 3:42:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Finance and AI Executive Patrick Fleury to Join Corvex Board of Directors as Company Scales AI Cloud Infrastructure Platform and Prepares to Launch Token Factory

    TeraWulf CFO brings deep expertise across data center transactions, energy-advantaged digital infrastructure campuses, and large-scale capital formationARLINGTON, Va., June 26, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced the appointment of Patrick A. Fleury to its Board of Directors, upon election at the Company's upcoming annual meeting. Fleury currently serves as Chief Financial Officer of TeraWulf Inc. (NASDAQ:WULF), a publicly traded developer, owner

    6/26/26 9:00:00 AM ET
    $MOVE
    $WULF
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    EDP Services
    Technology

    $MOVE
    Financials

    Live finance-specific insights

    View All

    Corvex Reports Q1 2026 Financial Results and Provides Business Update

    Conference Call at 4:30 PM ET / 1:30 PM PTARLINGTON, Va., May 19, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, reported first quarter 2026 results and provided a business update. Reported Q1'26 Highlights:Completed acquisition of Corvex OpCo on March 19, 2026, transitioning the Company's primary business to AI cloud computing and renaming Movano Inc. to Corvex, Inc., effective March 23, 2026.Including 12 days of Corvex OpCo operations in the period, Q1'26 total revenue w

    5/19/26 4:06:00 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corvex to Host First Quarter 2026 Earnings Call on Tuesday, May 19, 2026

    Conference Call at 4:30 PM ET/ 1:30 PM PTARLINGTON, Va., May 11, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today announced that it will hold its first quarter 2026 earnings call on Tuesday, May 19, 2026 at 4:30 pm ET / 1:30 pm PT. Management will host a conference call and live audio webcast to discuss first quarter 2026 results and provide a business update. The live webcast of the earnings conference call can be accessed at the Corvex Investor Relations website at i

    5/11/26 8:30:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CORVEX, INC. ANNOUNCES ADDITIONAL DETAILS OF SPECIAL 35.8% STOCK DIVIDEND FOR SHAREHOLDERS OF RECORD ON MARCH 30, 2026

    ARLINGTON, Va., March 24, 2026 /PRNewswire/ -- Corvex, Inc. (NASDAQ:MOVE) ("Corvex" or the "Company") today announced additional details regarding the special 35.8% stock dividend (the "Stock Dividend") previously announced on March 19, 2026.  Each stockholder of record as of the close of business on March 30, 2026 will be entitled to receive a 35.8% stock dividend at no cost and with no action required on the part of the stockholder.For example, a stockholder holding 10,000 shares of Corvex common stock, par value $0.0001 per share (the "Common Stock") as of the close of tradin

    3/24/26 8:00:00 AM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MOVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    4/10/24 4:39:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Movano Inc. (Amendment)

    SC 13G/A - Movano Inc. (0001734750) (Subject)

    4/9/24 5:41:12 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Movano Inc.

    SC 13G - Movano Inc. (0001734750) (Subject)

    2/4/22 4:20:05 PM ET
    $MOVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care